On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...